Tilomisole (Wy 18251) 是一种具有抗炎活性的苯并咪唑噻唑实验药物。与左旋咪唑相比，Tilomisole 引起的粒细胞缺乏症较少，但保留了免疫调节能力。Tilomisole 口服有效。Tilomisole 具有研究癌症和炎症的潜力。

Tilomisole (Wy 18251) is a benzimidazothiazole experimental drug with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation [1] [2].

58433-11-7

C17H11ClN2O2S

342.8

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years